BTK and B-cell chronic lymphocytic leukemia: The new anti-CD20 monoclonal antibodies and targeted therapies towards BTK or BCL2, either alone or in combination, proved to be more active, better tolerated than chemoimmunotherapy, and to increase the survival of CLL patients [1,2,3].